More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

How does sustainability fit into overall investment decisions and practices? Is it a way to achieve competitive advantage? A recent PwC analysis says "yes" as it examines the role of sustainability in financial decision-making. What is the...
DCAT Value Chain Insights

The BRIC (Brazil, Russia, India, and China) countries are important engines of growth for the global pharmaceutical industry, but how does manufacturing activity align with that growth? A look into Russia's pharmaceutical market and the...
DCAT Value Chain Insights

How did pharmaceutical and biopharmaceutical companies fare in the first quarter? Now that financial results are in, an analysis of first-quarter results. The pharmaceutical and biopharmaceutical industry offered mixed revenue results for the...
DCAT Value Chain Insights

In 2013, 17 new orphan drugs were launched in the US, the highest number of orphan drugs introduced to the US market in more than a decade. As pharmaceutical companies seek ways to improve R&D productivity and reach commercialization, they are...
DCAT Value Chain Insights

Following a decline in 2012, nominal and real-per-capita spending for medicines increased in the US, but growth in spending for medicines in the US remains at historical lows. The US pharmaceutical market recovered in 2013, posting positive...